JPMAM, UBS GWM launch genetic therapies fund

Elisabeth Reyes
clock • 1 min read

JP Morgan Asset Management has launched the JPMAM Genetic Therapies fund in partnership with UBS Global Wealth Management, to target what it sees as "disruptive technology for the pharmaceutical and biotechnology industry". An active equity strategy, the fund uses research done by UBS Global Wealth Management's Chief Investment Office within its Longer Term Investments framework, and is being distributed by UBS initially. Co-managers are Yazann Romahi, Berkan Sesen and Aijaz Hussein, who sit within JPMAM's Quantitative Beta Strategies team, which specialises on quantitative portfolio ...

To continue reading this article...

Join International Investment

Join International Investment today

Unlock members-only benefits:

  • Unlimited access to real-time news, industry insights, video features and market intelligence
  • Stay ahead of the curve with spotlights on international financial centres, regional trends international advice and global industry leaders
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Hear the latest cross jurisdictional developments in wealth planning, tax, regulation, investing, retirement and protection
  • Members-only access to the Editor’s weekly news roundup newsletter
  • Members-only access to analysis via our exclusive industry polls
  • Be the first to hear about our events and awards programmes

Join now


Already a International Investment member?